Verily Life Sciences, a South San Francisco, CA, USA-based Alphabet company that provides healthcare solutions for global markets, received an $800M investment.
Temasek, a Singapore-based investment company, will take a minority stake in the company and will nominate a director to its operating board. A majority of the investment will be funded in the coming days, with the remainder scheduled to be funded in the second half of 2017.
Led by Andrew Conrad, CEO, Verily Life Sciences is a life sciences research and engineering organization focused on applying scientific and technological advances to significant problems in health and biology in global markets.
The company operates by combining capabilities in data organization and analytics services with scientific and product engineering expertise to create tools and platforms that capture and organize a broad set of health data to make it actionable. It then partners with life sciences, medical device and government organizations to leverage domain expertise and resources that enable faster development and advancements and deployment at scale.